New certification scheme for SMEs with advanced therapies

Small and medium-sized companies (SMEs) that have done preclinical work on developing advanced therapies, such as gene or cell products, will be eligible to receive a certificate from the European Medicines Agency (EMEA) verifying that their preclinical data package meets European regulatory standards for quality and safety.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom